B. Riley Securities Initiates Coverage On Arcturus Therapeutics with Buy Rating, Announces Price Target of $22
Arcturus Therapeutics
Arcturus Therapeutics ARCT | 0.00 |
B. Riley Securities analyst Mayank Mamtani initiates coverage on Arcturus Therapeutics (NASDAQ:
ARCT) with a Buy rating and announces Price Target of $22.
